{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:19:56Z","timestamp":1787959196676,"version":"build-2784847793"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cutaneous T-cell lymphomas (CTCLs) are a group of rare and heterogenous diseases. There is currently no curative treatment for patients with advanced mycosis fungoides (MF) and S\u00e9zary syndrome (SS). The European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of MF\/SS have been updated and focus on recently available treatments. Peginterferon, a new form of interferon, has a favourable risk\u2013benefit profile for the treatment of patients with CTCL. Recently approved monoclonal antibodies (mABs) have completely modified the treatment algorithm of advanced CTCL treatment. Brentuximab vedotin is very efficient for tumours and transformed MF. Mogamulizumab can induce long-term remission in patients with SS. An international trial of lacutamab has recently been completed, for both SS and MF. Numerous novel targets have been identified, and several new mABs have been shown to be able to enhance specific immune responses and to induce targeted antibody-dependent cytotoxicity and cytophagocytosis. These new antibodies warrant further evaluation in controlled trials. Kinase inhibitors and chimeric antigen receptor T-cell therapy are promising new treatments. Finally, recent studies have demonstrated that allogeneic haematopoietic stem-cell transplantation can increase survival and quality of life in patients with advanced CTCL.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf105","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:40:34Z","timestamp":1743223234000},"page":"11-15","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic advances for cutaneous T-cell lymphoma"],"prefix":"10.1093","volume":"193","author":[{"given":"Martine","family":"Bagot","sequence":"first","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9 , 1 Avenue Claude Vellefaux, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"2025062515091103000_ljaf105-B1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/bjd.19644","article-title":"Epidemiological changes in cutaneous lymphomas: an analysis of 8,593 patients from the French Cutaneous Lymphoma Registry","volume":"184","author":"Dobos","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025062515091103000_ljaf105-B2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025062515091103000_ljaf105-B3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jaad.2024.07.1501","article-title":"Approach to mycosis fungoides in children: consensus-based recommendations","volume":"91","author":"Zvulunov","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025062515091103000_ljaf105-B4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/bjd\/ljae152","article-title":"Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides\/S\u00e9zary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study","volume":"191","author":"Mitsunaga","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025062515091103000_ljaf105-B5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"; ALCANZA study group. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"2025062515091103000_ljaf105-B6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025062515091103000_ljaf105-B7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","article-title":"Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study","volume":"133","author":"Dummer","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025062515091103000_ljaf105-B8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.18215","article-title":"Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas","volume":"181","author":"Dumont","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025062515091103000_ljaf105-B9","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.18806","article-title":"Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides","volume":"182","author":"Andr\u00e9","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025062515091103000_ljaf105-B10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025062515091103000_ljaf105-B11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/bjd.21030","article-title":"Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides","volume":"187","author":"Wang","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025062515091103000_ljaf105-B12","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing and disease control in\u00a0mogamulizumab-treated CTCL patients","volume":"139","author":"de Masson","year":"2022","journal-title":"Blood"},{"key":"2025062515091103000_ljaf105-B13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjd.21018","article-title":"Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in S\u00e9zary syndrome","volume":"186","author":"Roelens","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025062515091103000_ljaf105-B14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025062515091103000_ljaf105-B15","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","article-title":"Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma","volume":"12","author":"Phillips","year":"2021","journal-title":"Nat Commun"},{"key":"2025062515091103000_ljaf105-B16","doi-asserted-by":"crossref","first-page":"2115197","DOI":"10.1080\/2162402X.2022.2115197","article-title":"Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in S\u00e9zary syndrome","volume":"11","author":"Su","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025062515091103000_ljaf105-B17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/bjd.18481","article-title":"Revisiting the initial diagnosis and blood staging of mycosis fungoides and S\u00e9zary syndrome with the KIR3DL2 marker","volume":"182","author":"Roelens","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025062515091103000_ljaf105-B18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025062515091103000_ljaf105-B19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.34005","article-title":"Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma","volume":"128","author":"Leupin","year":"2022","journal-title":"Cancer"},{"key":"2025062515091103000_ljaf105-B20","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/bloodadvances.2021005714","article-title":"Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models","volume":"6","author":"Wu","year":"2022","journal-title":"Blood Adv"},{"key":"2025062515091103000_ljaf105-B21","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/bloodadvances.2021006512","article-title":"CCR8 is a new therapeutic target in cutaneous T-cell lymphomas","volume":"6","author":"Giustiniani","year":"2022","journal-title":"Blood Adv"},{"key":"2025062515091103000_ljaf105-B22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jid.2023.01.009","article-title":"CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas","volume":"143","author":"Ta","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2025062515091103000_ljaf105-B23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","article-title":"Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"2025062515091103000_ljaf105-B24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"key":"2025062515091103000_ljaf105-B25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jid.2023.02.017","article-title":"Blockade of the immune checkpoint CD47 by TTI-621 potentiates the response to anti-PD-L1 in cutaneous T-cell lymphoma","volume":"143","author":"Han","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2025062515091103000_ljaf105-B26","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"key":"2025062515091103000_ljaf105-B27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025062515091103000_ljaf105-B28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"key":"2025062515091103000_ljaf105-B29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bmt.2011.16","article-title":"Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas","volume":"47","author":"Delioukina","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2025062515091103000_ljaf105-B30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"key":"2025062515091103000_ljaf105-B31","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025062515091103000_ljaf105-B32","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf105\/62704663\/ljaf105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/1\/11\/62704663\/ljaf105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/1\/11\/62704663\/ljaf105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:09:22Z","timestamp":1750878562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/1\/11\/8093402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,22]]},"published-print":{"date-parts":[[2025,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf105","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,22]]}}}